Belsomra vs. Dayvigo vs. Quviviq: Comparing All Three DORA Sleep Medications

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | March 2, 2026 | 9 min read

Belsomra, Dayvigo, and Quviviq are all dual orexin receptor antagonists (DORAs) — but their half-lives, dosing, and next-day alertness profiles differ significantly for PI patients.

Belsomra vs. Dayvigo vs. Quviviq: Comparing All Three DORA Sleep Medications

Belsomra (suvorexant), Dayvigo (lemborexant), and Quviviq (daridorexant) are all dual orexin receptor antagonists (DORAs) — a class of sleep medications that block the brain's wake-promoting orexin signal rather than broadly sedating the central nervous system. All three are FDA-approved for insomnia and Schedule IV controlled substances, but their pharmacokinetic profiles, approved doses, and clinical strengths differ in ways that matter for personal injury patients and the attorneys managing their cases.

• Belsomra (suvorexant) was the first FDA-approved DORA (2014) and has the longest real-world safety record
• Dayvigo (lemborexant, 2019) offers strong sleep maintenance with a longer half-life — best for patients who wake repeatedly through the night
• Quviviq (daridorexant, 2022) has the shortest half-life (~8 hours) and the best next-day alertness profile of the three
• All three are Schedule IV, require a prescription, and document physician-diagnosed insomnia severe enough to warrant pharmacotherapy
• LienScripts generates a POGOS (Pharmacy-Organized General Occurrence Summary) report for every case, providing pharmacist-signed documentation of sleep medication regimens for demand packages

What All Three Drugs Have in Common

Before examining the differences, understanding the shared mechanism explains why DORAs have largely replaced older sleep agents in modern personal injury medication management.

The orexin system (also called the hypocretin system) is the brain's primary wake-promotion pathway. Orexin peptides bind to two receptor subtypes — OX1R and OX2R — to maintain wakefulness. All three DORAs block both receptor subtypes simultaneously, selectively removing this wake-promoting signal without broadly suppressing CNS function.

For personal injury patients, this mechanism is particularly relevant. Pain, post-traumatic stress, and hyperarousal from motor vehicle accidents or other injuries keep orexin signaling chronically elevated — actively preventing sleep even when the patient is physically exhausted. A DORA directly addresses this pathway, which is clinically distinct from a benzodiazepine or Z-drug that broadly sedates the brain.

Clinical documentation value shared by all three:

• Physician-diagnosed insomnia requiring prescription pharmacotherapy
• Selection of a mechanism-specific, modern agent (not a non-specific sedative)
• Documented functional impairment affecting daily life, cognitive function, and pain experience
• Monthly refill records that timeline sleep impairment throughout the recovery period

The Three-Way Comparison

Belsomra (Suvorexant): First-Generation DORA With a Decade of Data

Belsomra received FDA approval in 2014 as the world's first dual orexin receptor antagonist, making it by far the most clinically documented drug in this class. As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "Belsomra's decade of post-market data gives prescribers confidence in its safety profile that newer DORAs simply haven't had time to accumulate. For a PI patient who requires ongoing sleep pharmacotherapy across a long recovery, that track record matters."

Pharmacokinetics: Belsomra has a half-life of approximately 12 hours — longer than Quviviq but shorter than Dayvigo. At the maximum approved dose (20mg), some patients experience next-day residual effects, though less so than with Dayvigo 10mg.

Doses: The 10mg starting dose is well-tolerated with minimal next-day effects. The 15mg and 20mg doses provide stronger sleep maintenance efficacy. For elderly patients or those with hepatic impairment, 10mg is the recommended ceiling.

Clinical positioning: Belsomra is most appropriate when a treating physician wants a proven, well-studied agent with extensive post-marketing safety data. For PI cases with a long recovery timeline — spinal injuries, complex orthopedic injuries requiring multiple surgeries — the established record of Belsomra can be clinically reassuring.

[!KEY] A Belsomra prescription at the 20mg dose documents sleep impairment significant enough that the prescriber selected the highest approved DORA dose — a clinical decision that reflects the severity and persistence of the patient's sleep disruption.

Dayvigo (Lemborexant): The Sleep Maintenance Specialist

Dayvigo (lemborexant) received FDA approval in 2019 as a second-generation DORA with improved receptor binding characteristics compared to suvorexant. Its defining pharmacokinetic feature is its long half-life — approximately 17 to 19 hours at the 10mg dose — which provides strong sleep maintenance throughout the full night but can result in meaningful next-day residual concentrations.

Clinical positioning: Dayvigo is best suited for PI patients whose primary complaint is sleep fragmentation — falling asleep without difficulty, but waking repeatedly throughout the night due to positional pain from back injuries, shoulder injuries, or neck injuries sustained in a motor vehicle accident.

The 10mg dose specifically targets sleep maintenance outcomes. In clinical trials, lemborexant 10mg showed statistically significant improvement in wake time after sleep onset (WASO) — the measure most closely correlated with the pattern of pain-fragmented sleep that characterizes many PI patients.

Next-day alertness caveat: The same long half-life that provides strong maintenance creates a tradeoff. Patients taking Dayvigo 10mg who need full cognitive alertness the following morning — for depositions, attorney meetings, return-to-work situations, or early medical appointments — may experience residual somnolence. The 5mg dose mitigates this but provides less sleep maintenance benefit.

[!KEY] A Dayvigo 10mg prescription specifically documents pain-fragmented sleep maintenance difficulty — the pattern of repeated nighttime waking that is the hallmark of chronic pain-disrupted sleep — and is clinically distinct from difficulty falling asleep.

Quviviq (Daridorexant): The Next-Day Alertness Advantage

Quviviq (daridorexant) received FDA approval in January 2022 as the newest DORA, and its development was explicitly focused on improving next-day residual effects compared to earlier DORAs. With a half-life of approximately 8 hours, Quviviq is largely metabolized and eliminated before the patient needs to function the following morning.

Clinical positioning: Quviviq is the preferred choice when next-day alertness is a clinical priority — patients with depositions, medical evaluations, return-to-work obligations, or early caregiving responsibilities. The 50mg dose provides strong efficacy for both sleep onset and sleep maintenance while preserving morning function better than comparator doses of Dayvigo or Belsomra.

Doses: The 25mg dose addresses mild-to-moderate insomnia and serves as a starting point for patients sensitive to sleep medications. The 50mg dose is indicated for more significant insomnia with both onset and maintenance components, and is the dose most studied in clinical trials.

In the pivotal ADVANCE-1 and ADVANCE-2 trials, daridorexant 50mg showed statistically significant improvements in sleep onset latency, WASO, and self-reported next-morning alertness — a combined endpoint profile that no earlier DORA had simultaneously achieved.

[!KEY] Quviviq 50mg is the only DORA with clinical trial data demonstrating simultaneous improvement in sleep onset, sleep maintenance, and next-day daytime functioning — making it the most appropriate choice when PI patient functional obligations require full morning alertness.

Which DORA for Which PI Patient Profile?

Choose Belsomra (20mg) when:

• The recovery timeline is long and the prescriber values an agent with a decade of post-market safety data
• The patient has a complex medical history where established drug interaction profiles matter
• The patient or prescriber is unfamiliar with newer DORAs and wants to start with the most-studied option
• Moderate sleep maintenance support is needed without committing to the longer half-life of Dayvigo

Choose Dayvigo (10mg) when:

• The primary complaint is repeated nighttime waking from pain — falling asleep is not the problem, but staying asleep is
• The patient wakes 3 to 5 times per night, unable to achieve sustained restorative sleep due to positional discomfort from orthopedic injuries
• Morning function is less critical (patient is on medical leave, not driving early in the day)
• Maximum sleep maintenance efficacy is the clinical priority

Choose Quviviq (50mg) when:

• The patient has depositions, attorney meetings, or work obligations the following morning
• Driving in the morning is required
• Both sleep onset and sleep maintenance are problems, but the patient cannot tolerate next-day grogginess
• The patient previously experienced significant next-day impairment from Belsomra or Dayvigo

Half-Life as the Central Clinical Variable

The most practical way to understand the three-drug comparison is through half-life, which determines how much drug remains in the patient's system when they need to function:

Quviviq (~8 hours): If taken at 10 PM, roughly one half-life has passed by 6 AM. At that point, plasma concentrations are well below the range associated with significant sedation for most patients. The drug is largely "done" by morning.

Belsomra (~12 hours): If taken at 10 PM, one half-life has passed by 10 AM. Meaningful concentrations persist through morning hours. Next-day effects are present but typically less pronounced than Dayvigo.

Dayvigo (~17–19 hours at 10mg): If taken at 10 PM, one half-life has not yet passed at 6 AM. The drug remains at significant concentrations well into the following afternoon, providing sustained sleep maintenance but creating the most next-day residual effect of the three.

This half-life gradient directly maps onto the clinical use cases: Quviviq for morning-function-sensitive patients, Belsomra for the middle ground, Dayvigo for patients where nighttime maintenance outweighs next-day alertness needs.

PI Documentation: All Three Drugs Tell the Same Core Story

Regardless of which DORA a treating physician selects, a prescription for any of the three documents the same foundational clinical facts for a personal injury case:

1. Physician-diagnosed insomnia — the prescribing physician determined sleep impairment was severe enough to require a prescription Schedule IV controlled substance
2. Mechanism-specific treatment — the prescriber chose a current-generation DORA rather than a benzodiazepine, antihistamine, or OTC option, reflecting deliberate clinical judgment about the nature of the patient's sleep disorder
3. Documented functional impairment — sleep disruption is not a subjective complaint but a clinical finding that required pharmacological management
4. Ongoing records — monthly refill history creates an objective, pharmacy-sourced timeline of persistent sleep impairment throughout the recovery period

The specific drug chosen adds a layer of clinical detail. Dayvigo 10mg documents sleep fragmentation; Quviviq 50mg documents a patient whose functional obligations required the most next-day-alert DORA available; Belsomra 20mg documents a patient whose sleep impairment was severe enough to require the maximum dose of the original DORA.

LienScripts generates a POGOS (Pharmacy-Organized General Occurrence Summary) report for every case, providing pharmacist-signed documentation of the patient's full medication regimen — including DORA prescriptions — for demand packages. This report compiles the clinical narrative of medication use across the entire treatment period in a format designed for attorney review.

Combination Prescribing: When DORAs Appear Alongside Other PI Medications

DORA prescriptions rarely appear in isolation in PI cases. Treating physicians managing complex injury cases frequently co-prescribe sleep medications alongside other agents:

With muscle relaxants (cyclobenzaprine, tizanidine): Muscle spasm is a primary driver of sleep disruption in cervical and lumbar injury cases. A treating physician who prescribes both a muscle relaxant and a DORA is documenting that the sleep impairment has a musculoskeletal component requiring management on two pharmacological fronts.

With PTSD medications (Rexulti/brexpiprazole, prazosin): PTSD from motor vehicle accidents produces hyperarousal-driven insomnia — a distinct mechanism from pain-fragmented sleep. Concurrent PTSD and DORA prescriptions document both psychiatric and sleep consequences of the injury, each requiring independent management.

With neuropathic pain agents (gabapentin, Lyrica): When neuropathic pain is the primary sleep disruptor, gabapentin has some intrinsic sleep-promoting properties and is sometimes used as first-line. A treating physician who adds a DORA on top of gabapentin is documenting that the sleep impairment was severe enough to require dedicated sleep pharmacotherapy beyond what the pain medication alone provided.

A Note on Generic Availability

As of the date of this post, none of the three DORAs — Belsomra, Dayvigo, or Quviviq — have FDA-approved generic equivalents available in the United States. All three remain brand-name-only medications. This is clinically relevant in PI cases because treating physicians prescribing any of these medications are prescribing a brand agent with no generic substitution available at the pharmacy level.

For personal injury patients without insurance or with inadequate coverage for brand sleep medications, pharmacy lien programs like LienScripts provide access at $0 upfront, with the lien satisfied at settlement.

Related Resources

• Quviviq vs. Dayvigo: Comparing Sleep Medications for Personal Injury Patients
• Non-Opioid Pain Management in Personal Injury Cases: 2025 Update
• Why PI Patients Often Need Multiple Medications